Regenxbio Inc (RGNX)
8.76
-0.03
(-0.34%)
USD |
NASDAQ |
Nov 04, 16:00
8.765
0.00 (0.00%)
Pre-Market: 20:00
Regenxbio Cash from Operations (Quarterly): -45.50M for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -45.50M |
| March 31, 2024 | -55.46M |
| December 31, 2023 | -40.76M |
| September 30, 2023 | -49.41M |
| June 30, 2023 | -47.32M |
| March 31, 2023 | -80.92M |
| December 31, 2022 | -39.37M |
| September 30, 2022 | -50.46M |
| June 30, 2022 | -61.75M |
| March 31, 2022 | -55.91M |
| December 31, 2021 | 341.50M |
| September 30, 2021 | -42.50M |
| June 30, 2021 | -36.07M |
| March 31, 2021 | -44.05M |
| December 31, 2020 | 39.47M |
| September 30, 2020 | -36.46M |
| June 30, 2020 | -21.50M |
| March 31, 2020 | -35.57M |
| December 31, 2019 | -25.51M |
| Date | Value |
|---|---|
| September 30, 2019 | -29.15M |
| June 30, 2019 | -23.75M |
| March 31, 2019 | -29.30M |
| December 31, 2018 | -4.14M |
| September 30, 2018 | -19.56M |
| June 30, 2018 | 70.21M |
| March 31, 2018 | 58.13M |
| December 31, 2017 | -13.83M |
| September 30, 2017 | -17.14M |
| June 30, 2017 | -9.549M |
| March 31, 2017 | -17.48M |
| December 31, 2016 | -20.42M |
| September 30, 2016 | -11.82M |
| June 30, 2016 | -8.43M |
| March 31, 2016 | -7.887M |
| December 31, 2015 | -4.443M |
| September 30, 2015 | -8.395M |
| June 30, 2015 | -8.002M |
| March 31, 2015 | -1.675M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-80.92M
Minimum
Mar 2023
341.50M
Maximum
Dec 2021
-20.40M
Average
-42.50M
Median
Sep 2021
Cash from Operations (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 14.94M |
| Catalyst Pharmaceuticals Inc | 64.14M |
| Vertex Pharmaceuticals Inc | -3.754B |
| Edgewise Therapeutics Inc | -26.10M |
| Entrada Therapeutics Inc | 39.83M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.268M |
| Cash from Financing (Quarterly) | -9.445M |
| Free Cash Flow | -194.72M |
| Free Cash Flow Per Share (Quarterly) | -0.9085 |
| Free Cash Flow to Equity (Quarterly) | -45.97M |
| Free Cash Flow Yield | -48.25% |